We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug combinations.
Galapagos NV (Euronext & NASDAQ: GLPG) announced that its Board of Directors created 150,000 warrants under a new warrant plan for the benefit of an employee of a subsidiary of the Company.